ABCB1 and breast carcinoma: Similarly, combining anti-Nectin-4 ADCs with multidrug resistance protein 1 (MDR1)/P-glycoprotein inhibitors reversed resistance in vivo while maintaining tolerable toxicity levels in breast cancer models[32].